Targeting HOX transcription factors in prostate cancer

BMC Urology

Volumn 14, Issue 1, 2014, Pages

  Morgan, Richard ^a   Boxall, Angie ^a   Harrington, Kevin J ^b   Simpson, Guy R ^a   Michael, Agnieszka ^a   Pandha, Hardev S ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

HOX; HXR9; PBX; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; HXR9; PBX PROTEIN; PROTEIN INHIBITOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; GENE DISRUPTION; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENE TARGETING; HOX GENE; INOCULATION; MALE; MOUSE; NONHUMAN; ONCOGENE C FOS; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PEPTIDES; PROSTATIC NEOPLASMS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84893158639     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-14-17     Document Type: Article

References (35)

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, Int J Cancer 2010 127 2893 2917
2. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience. DiBlasio CJ, Malcolm JB, Hammett J, Wan JY, Aleman MA, Patterson AL, Wake RW, Derweesh IH, BJU Int 2009 104 1208 1214
3. Management of metastatic castration-resistant prostate cancer: recent advances. Mukherji D, Eichholz A, De Bono JS, Drugs 2012 72 1011 1028
4. The HOX genes and their roles in oncogenesis. Shah N, Sukumar S, Nat Rev Cancer 2010 10 361 371
5. Pbx modulation of HOX homeodomain amino-terminal arms establishes different DNA-binding specificities across the HOX locus. Chang CP, Brocchieri L, Shen WF, Largman C, Cleary ML, Mol Cell Biol 1996 16 1734 1745
6. A conserved motif N-terminal to the DNA-binding domains of myogenic bHLH transcription factors mediates cooperative DNA binding with pbx-Meis1/Prep1. Knoepfler PS, Bergstrom DA, Uetsuki T, Dac-Korytko I, Sun YH, Wright WE, Tapscott SJ, Kamps MP, Nucleic Acids Res 1999 27 3752 3761
7. Identifying HOX paralog groups by the PBX-binding region. Morgan R, In der Rieden P, Hooiveld MH, Durston AJ, Trends Genet 2000 16 66 67
8. Homeobox genes and axial patterning. McGinnis W, Krumlauf R, Cell 1992 68 283 302
9. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Miller GJ, Miller HL, van Bokhoven A, Lambert JR, Werahera PN, Schirripa O, Lucia MS, Nordeen SK, Cancer Res 2003 63 5879 5888
10. The homeodomain protein HOXB13 regulates the cellular response to androgens. Norris JD, Chang CY, Wittmann BM, Kunder RS, Cui H, Fan D, Joseph JD, McDonnell DP, Mol Cell 2009 36 405 416
11. Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation. Waltregny D, Alami Y, Clausse N, de Leval J, Castronovo V, Prostate 2002 50 162 169
12. The role of HOX genes in malignant myeloid disease. Eklund EA, Curr Opin Hematol 2007 14 85 89
13. Posterior HOX gene expression and differential androgen regulation in the developing and adult rat prostate lobes. Huang L, Pu Y, Hepps D, Danielpour D, Prins GS, Endocrinology 2007 148 1235 1245
14. Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma. Ando H, Natsume A, Senga T, Watanabe R, Ito I, Ohno M, Iwami K, Ohka F, Motomura K, Kinjo S, Ito M, Saito K, et al. Cancer Chemother Pharmacol 2014 73 53 60
15. Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Daniels TR, Neacato II, Rodriguez JA, Pandha HS, Morgan R, Penichet ML, Leukemia 2010 24 1555 1565
16. The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway. Errico MC, Felicetti F, Bottero L, Mattia G, Boe A, Felli N, Petrini M, Bellenghi M, Pandha HS, Calvaruso M, Tripodo C, Colombo MP, et al. Int J Cancer 2013 133 879 892
17. PBX3 is an important cofactor of HOXA9 in leukemogenesis. Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H, Jiang X, Hong GM, Kunjamma RB, Ren H, He C, Wang CZ, et al. Blood 2013 121 1422 1431
18. Targeting the HOX/PBX dimer in breast cancer. Morgan R, Boxall A, Harrington KJ, Simpson GR, Gillett C, Michael A, Pandha HS, Breast Cancer Res Treat 2012 136 389 398
19. Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Morgan R, Pirard PM, Shears L, Sohal J, Pettengell R, Pandha HS, Cancer Res 2007 67 5806 5813
20. Targeting HOX and PBX transcription factors in ovarian cancer. Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS, BMC Cancer 2010 10 89
21. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Plowright L, Harrington KJ, Pandha HS, Morgan R, Br J Cancer 2009 100 470 475
22. Disrupting the interaction between HOX and PBX causes necrotic and apoptotic cell death in the renal cancer lines CaKi-2 and 769-P. Shears L, Plowright L, Harrington K, Pandha HS, Morgan R, J Urol 2008 180 2196 2201
23. Isolation of a human prostate carcinoma cell line (DU 145). Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF, Int J Cancer 1978 21 274 281
24. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW, Invest Urol 1979 17 16 23
25. LNCaP model of human prostatic carcinoma. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP, Cancer Res 1983 43 1809 1818
26. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications part 2. Tumorigenic cell lines. Webber MM, Bello D, Quader S, Prostate 1997 30 58 64
27. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC, et al. Lab Anim 1988 22 195 201
28. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Sauvageau G, Lansdorp PM, Eaves CJ, Hogge DE, Dragowska WH, Reid DS, Largman C, Lawrence HJ, Humphries RK, Proc Natl Acad Sci U S A 1994 91 12223 12227
29. Human colorectal carcinogenesis is associated with deregulation of homeobox gene expression. Vider BZ, Zimber A, Hirsch D, Estlein D, Chastre E, Prevot S, Gespach C, Yaniv A, Gazit A, Biochem Biophys Res Commun 1997 232 742 748
30. c-Fos is a mediator of the c-myc-induced apoptotic signaling in serum-deprived hepatoma cells via the p38 mitogen-activated protein kinase pathway. Kalra N, Kumar V, J Biol Chem 2004 279 25313 25319
31. The proto-oncoprotein c-Fos negatively regulates hepatocellular tumorigenesis. Mikula M, Gotzmann J, Fischer AN, Wolschek MF, Thallinger C, Schulte-Hermann R, Beug H, Mikulits W, Oncogene 2003 22 6725 6738
32. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG, Collins SI, Searle PF, Hull D, Peers E, Chester J, Wallace DM, et al. Mol Ther 2009 17 1292 1299
33. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, Tabata K, Ren C, Goltsov AA, Mims MP, Hayes TG, Ittmann MM, et al. Clin Cancer Res 2011 17 7174 7182
34. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Thirukkumaran CM, Nodwell MJ, Hirasawa K, Shi ZQ, Diaz R, Luider J, Johnston RN, Forsyth PA, Magliocco AM, Lee P, Nishikawa S, Donnelly B, et al. Cancer Res 2010 70 2435 2444
35. Chou R, Dana T, Bougatsos C, Fu R, Blazina I, Gleitsmann K, Rugge JB, Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendationed Rockville (MD): Agency For Healthcare Research and Quality 2011